การศึกษาการเพิ่มของน้ำหนักตัวและภาวะเมตาบอลิก ในผู้ติดเชื้อเอชไอวี (HIV) ที่ได้รับการรักษาด้วยยาต้านไวรัส KOCITAF และ TLD ติดตามผล 12 เดือน โรงพยาบาลศูนย์อุดรธานี

Watcharaphon Tangsawad

Authors

Watcharaphon Tangsawad Department of Internal Medicine, Udonthani Hospital

Keywords:

Antiretroviral therapy, TLD, KOCITAF, Body weight, Metabolic syndrome

Abstract

This retrospective study examined changes in body weight and metabolic status among 103 adult HIV patients treated with either KOCITAF (n=52) or TLD (n=51). Data were collected from medical records from January 2023 to December 2025, with outcomes measured over a 12-month period and tracked at various time points within each group to monitor the effects of antiretroviral therapy on patients.

The results showed that at month 12, the KOCITAF group had a mean body weight increase of 1.90 ± 4.59 kg (95% CI: 0.66 to 3.15; p = 0.001). Renal function (eGFR) improved (3.59 ± 9.88 mL/min/1.73 m² at 6 months; p = 0.011), and creatinine clearance also improved (4.87 ± 9.24 mL/min; p < 0.001). Renal function decline by CKD stage occurred in 6.7% of the KOCITAF group. In contrast, the TLD group showed a decline in eGFR (11.47 ± 11.08 mL/min/1.73 m²; p < 0.001), with renal function decline occurring in 27.1% of patients. Additionally, an eGFR decline of >10% from baseline was observed in 51.0% of the TLD group compared to 9.6% of the KOCITAF group (p < 0.001). After 12 months, triglyceride levels increased in the KOCITAF group (p = 0.012), and overall dyslipidemia occurred in 96.2% of the KOCITAF group compared to 51.0% in the TLD group (p < 0.001).

KOCITAF was associated with sustained weight gain after treatment initiation, while showing significant benefits for renal function. Dyslipidemia remains a potential complication of both regimens; therefore, close monitoring is needed to guide treatment planning and reduce the risk of further complications.

References

Punyawudho B, Wattanapreechanon P, Supaswud-Franks T, et al. The population pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV. CPT Pharmacometrics Syst Pharmacol 2025;14(1):95-104. doi: 10.1002/psp4.13244.

Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circ Res 2024;134(11):1515–45. doi: 10.1161/CIRCRESAHA.124.323891.

Zhu S, Wang W, He J, Duan W, Ma X, Guan H, et al. Higher cardiovascular disease risks in people living with HIV: a systematic review and meta-analysis. J Glob Health 2024;14:04078. doi: 10.7189/jogh.16.04078err1.

เกียรติ รักษ์รุ่งธรรม, กุลกัญญา โชคไพบูลย์กิจ, เพลินจันทร์ เชษฐโชติศักดิ์, สุวัฒน์ จริยาเลิศศักดิ์, ศศิโสภิณ เกีรติบูรณกุล, วินัย รัตนสุวรรณ, และคณะ. แนวทางการตรวจรักษาและป้องกันการติดเชื้อ HIV/AIDS ประเทศไทย พ.ศ. 2564/2565. นนทบุรี: กรมควบคุมโรค; 2565.

Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, et al. Antiretrovirals and weight change: weighing the evidence. Clin Infect Dis 2024;79(4):999–1005. doi: 10.1093/cid/ciae191.

Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis 2020;71(6):1379–89. doi: 10.1093/cid/ciz999.

Wood BR, Huhn GD. Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter? Open Forum Infect Dis 2021;8(12):ofab542. doi: 10.1093/ofid/ofab542.

Sjaarda A, Bernstein A, Sparks A, Saber S, Siegel M. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy. Infection 2022;50(2):407-12. doi: 10.1007/s15010-021-01687-6.

Yoo JJ, Jung EA, Kim SG, Kim YS, Kim MJ. Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis. J Int AIDS Soc 2024;27(9):e26358. doi: 10.1002/jia2.26358.

Mavarani L, Reinsch N, Albayrak-Rena S, Potthoff A, Hower M, Dolff S, et al. The association of HIV-specific risk factors with cardiovascular events in addition to traditional risk factors in people living with HIV. AIDS Res Hum Retroviruses 2024;40(4):235-245. doi: 10.1089/AID.2023.0055.

Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV. Circulation 2023;147(1):83–100. doi: 10.1161/CIRCULATIONAHA.122.057443.

Setpakdee R, Kiertiburanakul S. Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV. J Infect Public Health 2025;18(2):102630. doi: 10.1016/j.jiph.2024.102630.

Bailin SS, Koethe JR. Weight gain and antiretroviral therapy. Infect Dis Clin North Am 2024;38(3):499–515. doi: 10.1016/j.idc.2024.04.005.

Tovar Sanchez T, Mpoudi-Etame M, Kouanfack C, Delaporte E, Calmy A, Venter F, et al. Risks of metabolic syndrome in the ADVANCE and NAMSAL trials. Front Reprod Health 2023;5:1133556. doi: 10.3389/frph.2023.1133556.

Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, et al. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation. J Gastroenterol 2021;56(2):168-80. doi: 10.1007/s00535-020-01750-3.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS 2017;31(18):2503-14. doi: 10.1097/QAD.0000000000001675.

Markakis K, Tsachouridou O, Georgianou E, Pilalas D, Nanoudis S, Metallidis S. et al. Weight gain in HIV adults receiving antiretroviral treatment : Current Knowledge and Future Perspectives. Life (Basel) 2024;14(11):1367. doi: 10.3390/life14111367.

Orkin C, Antinori A, Rockstroh JK, Moreno-Guillén S, Martorell CT, Molina JM, et al. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy. AIDS 2024;38(7):983–91. doi: 10.1097/QAD.0000000000003865.

Sokhela S, Venter WDF, Bosch B, Woods J, McCann K, Akpomiemie G, et al. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. Open Forum Infect Dis 2024;11(3):ofae007. doi: 10.1093/ofid/ofae007.

Daar ES, Orkin C, Sax PE, Hagins D, Pozniak A, Workowski K, et al. Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. AIDS Res Ther 2025;22:45. doi: 10.1186/s12981-025-00732-w.

Zheng Y, Manson JE, Yuan C, Liang MH, Grodstein F, Stampfer MJ, et al. Associations of Weight Gain From Early to Middle Adulthood With Major Health Outcomes Later in Life. JAMA 2017 ;318(3):255-69. doi: 10.1001/jama.2017.7092.

Shah S, Pilkington V, Hill A. Is tenofovir disoproxil fumarate associated with weight loss? AIDS 2021;35(Suppl 2):S189-95. doi: 10.1097/QAD.0000000000003083.

Tanuma J, Jiamsakul A, Makane A, Avihingsanon A, Ng OT, Kiertiburanakul S, et al. Renal dysfunction during tenofovir use in a regional cohort of HIV-infected individuals in the Asia-Pacific. PLoS One 2016;11(8):e0161562. doi: 10.1371/journal.pone.0161562.